ClinicalTrials.gg
RecruitingNCT07937930Updated Nov 16, 2026

Exercise and Nutritional Intervention in Older Adults With Sarcopenia (Spleen-Kidney Deficiency Pattern)

An interventional study of nutritional intervention and Exercise in Sarcopenia in Elderly, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 82 studies in Sarcopenia with a site in China — 46 open to participants now, 51 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
21st of 51
120 · median 113
Started
2026
with 14 others
No phase
41 of 82
19 open now
Primary completion
2027-04
later than 25 of 50 live
Registered
82nd of 82
by date

Among the 82 studies in Sarcopenia with a site in China, this one is the 21st largest by planned enrollment of the 51 interventional ones that give a count, is one of 15 that started in 2026, is one of 41 with no phase, reaches primary completion later than 25 of the 50 other live ones, and was the 82nd registered.

Sarcopenia

1,330 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

46 of the 82 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

This study will enroll older adults with sarcopenia (Spleen-Kidney Deficiency Pattern) who will receive exercise and nutritional interventions. By assessing changes from baseline in DXA-measured appendicular muscle mass and other efficacy outcomes, the study aims to characterize the longitudinal changes in sarcopenia over a 24-week period and provide an external control for a future randomized, double-blind clinical trial of Peiyuan Guben Tongluo Ointment in older adults with sarcopenia (Spleen-Kidney Deficiency Pattern).

03

Conditions studied

  • Sarcopenia in Elderly

Browse trials for

Keywords

  • Sarcopenia in Elderly
  • Deficiency of Spleen and Kidney Yin
  • Peiyuan Guben Tongluo Ointment
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 60 and ≤ 90 years, regardless of sex.
  2. Meet the diagnostic criteria for sarcopenia in older adults according to both Western medicine and traditional Chinese medicine (TCM).
  3. Meet the TCM diagnostic criteria for the Spleen-Kidney Deficiency Pattern.
  4. Be willing to comply with the study intervention protocol, attend scheduled follow-up visits, and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe cerebrovascular diseases resulting in quadriplegia, long-term bedridden status, or complete loss of muscle strength (Grade 0); patients with muscle atrophy caused by various factors; or those unable to perform activities of daily living independently.
  2. Patients with Alzheimer's disease or vascular dementia accompanied by impaired consciousness, aphasia, delirium, inability to communicate or respond appropriately, or disorientation to time, place, or person.
  3. Patients with severe psychiatric disorders or depressive conditions who are receiving relevant pharmacological treatment.
  4. Patients with comorbid conditions that may affect nutritional status, including , severe infections, gastrointestinal bleeding, hepatic or renal insufficiency, or cardiac insufficiency.
  5. Patients who have received or are currently receiving traditional Chinese medicine treatment within the past month, or who have received medications affecting muscle contraction or relaxation within the past month.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Interventions

  • Dietary supplementnutritional intervention

    Provide protein and vitamin D supplementation.

  • BehavioralExercise

    Receive standardized Baduanjin training with unified movements; the training is conducted 3 times weekly, starting 3 hours after meals, with a duration of 30 minutes per session. Intervention

06

What researchers measure

Primary outcomes

  1. DXA-measured appendicular skeletal muscle mass

    Detected by dual-energy X-ray absorptiometry (GE Healthcare, DXA). The skeletal muscle mass index (SMI) is defined as the ratio of DXA-measured skeletal muscle mass to the square of height.

    Time frame: Baseline, week 12, week 24

Secondary outcomes

  1. Upper limb handgrip strength

    Use a hand dynamometer to record grip strength data for comparison.

    Time frame: Up to 24 weeks

  2. Handgrip strength

    Use a hand dynamometer to record grip strength data for comparison.

    Time frame: Baseline, week 12, week 24

  3. Timed Up and Go test (TUG)

    Subjects shall sit on a chair with a seat height of 46 cm, a straight backrest and armrests (armrest height approximately 65 cm). They are required to stand up with minimal assistance from the armrests. The total time is recorded from leaving the backrest to standing upright, walking 3 meters at their usual walking speed, turning around, walking back, and sitting down fully against the chair back. The average value of three trials is calculated. Elderly individuals who routinely use walking aids may use them during the test.

    Time frame: Baseline, week 12, week 24

  4. Berg Balance Scale (BBS)

    The scale consists of 14 items in total, including sitting to standing, standing to sitting, standing unsupported, standing with eyes closed, reaching forward with outstretched arms, turning 360 degrees, alternating foot placement on a step, single-leg standing, etc. All items take 10-15 minutes to complete. Each item is scored from a minimum of 0 points to a maximum of 4 points, with a total possible score of 56 points. A higher score indicates better balance function; a score below 40 points suggests an increased risk of falls.

    Time frame: Baseline, week 12, week 24

  5. TCM Syndrome Score

    In accordance with the scoring criteria specified in the 《Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs》, the total score for \*\*Spleen-Kidney Deficiency Syndrome\*\* was calculated.

    Time frame: Baseline, week 12, week 24

  6. Mini Nutritional Assessment (MNA)

    Nutritional status was evaluated using the Mini Nutritional Assessment (MNA). This scale comprehensively evaluates an individual's nutritional status through a series of questions covering body weight, dietary intake, mobility, mental state and other aspects. The full score of the scale is 30 points. Grading criteria: a total score ≥ 24 indicates good nutritional status; a score between 17 and 24 suggests risk of malnutrition; a total score below 17 confirms definite malnutrition.

    Time frame: Baseline, week 12, week 24

  7. Activities of Daily Living (ADL) Scale

    The Activities of Daily Living (ADL) scale, developed by American scholars Lawton and Brody in 1969, is a medical assessment tool composed of the Physical Self-Maintenance Scale (PSMS) and the Instrumental Activities of Daily Living (IADL). It is mainly used to evaluate subjects' functional levels in basic living skills such as feeding, dressing and mobility, as well as the ability to use instrumental tools. Constructed from two dimensions including PSMS and IADL, the scale contains a total of 10 assessment items.

    Time frame: Baseline. week 12, week 24

07

Study locations

1 of 1 sites recruiting
  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai Municipality 200437, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 5 months after the start.

Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 5 months is below that.

Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Oct 17, 2026
Primary completionEst.
Apr 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937930
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Responsible party
Fenghua Qian (Chief Physician, Shanghai Yueyang Integrated Medicine Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Oct 17, 2026
Primary completion
Apr 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Xiao ya Zhang, Undergraduate
Contact
2365672026@qq.com
+86 13645337890
Fenghua Qian, Undergraduate
principal investigator · Shanghai Yueyang Integrated Medicine Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion